Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
announced it will present the latest preclinical data from its
next- generation, proprietary, multi-specific NK cell engager
platform known as ANKET™ (
Antibody-based
NK cell
Engager
Therapeutics) at the Federation of Clinical
Immunology Societies (FOCIS) meeting. The presentation will take
place at 7 pm CEST today.
Specifically, Innate will share new data from
its tetra-specific ANKET molecule, which is the first NK cell
engager technology to engage activating receptors (NKp46 and CD16),
a tumor antigen and a cytokine (IL-2 variant) in a single molecule.
This latest innovation leverages the advantages of harnessing NK
cell effector functions against cancer cells and also provides
proliferation and activation signals targeted to NK cells. This
data set is built on Innate’s existing tri-specific NK cell engager
technology, which has demonstrated potent NK cell activation,
cytotoxicity and efficient control of tumor growth in preclinical
models.
In preclinical studies, tetra-specific ANKET
demonstrated in vitro the ability to induce human NK cell
proliferation, cytokine production and cytolytic activity against
cancer cells expressing the targeted antigen. Tetra-specific ANKET
also demonstrated in vivo anti-tumor efficacy in several tumor
models, allowing regression of established tumors as well as
control of metastasis, associated with increased NK cell
infiltration, cytokine and chemokine production at the tumor site.
ANKET showed also pharmacodynamic effect, low systemic cytokine
release and a manageable safety profile in non-human primates.
“We are excited to introduce the new evolution
of our ANKET platform at the FOCIS meeting today,” said Pr.
Eric Vivier, PhD, DVM, Chief Scientific Officer at Innate
Pharma. “NK cells play a critical role in the cancer
innate immunity cycle, and engaging them is an exciting path to
improve the therapeutic window for cancer treatment compared to T-
cell engagers. We believe the new findings obtained with our ANKET
technology capture its potential to advance meaningful outcomes for
patients. This advancement allows us to create an entirely new
class of molecules to induce synthetic immunity against
cancer. We look forward to sharing additional detail at
our upcoming IR R&D event.”
Innate’s lead ANKET asset, IPH6101 (SAR443579),
has shown anti-tumor activity in pre-clinical models, including
encouraging pharmacokinetic, pharmacodynamic and safety data in
preliminary non-human primate studies. In January, Sanofi made the
decision to progress this program into investigational new drug
(IND)-enabling studies. As part of the previously announced
research collaboration, the companies are also currently working on
the second research program.
Innate will provide more information on today’s
data at an upcoming online R&D presentation for the investor
community that is scheduled for 2 p.m. CEST on June 23, 2021.
About ANKET™
ANKET™ (Antibody-based
NK cell Engager
Therapeutics) is Innate Pharma's proprietary
platform for developing next-generation, multi-specific NK cell
engagers to treat certain types of cancer. The Company’s latest
innovation, its tetra-specific ANKET molecule, is the first NK cell
engager technology to engage activating receptors (NKp46 and CD16),
a tumor antigen and a cytokine (IL-2v) in a single molecule. This
leverages the advantages of harnessing NK cell effector functions
against cancer cells and also provides proliferation and activation
signals targeted to NK cells.
In preclinical studies, Innate's tri-1 and
tetra-specific technology has demonstrated potent NK cell
activation, cytotoxicity and efficient control of tumor growth in
preclinical models. This versatile fit-for-purpose technology is
creating an entirely new class of molecules to induce synthetic
immunity against cancer.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of
Natural Killer (NK) cell biology and has expanded its expertise in
the tumor microenvironment and tumor antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France, with a US
office in Rockville, MD, Innate Pharma is listed on Euronext Paris
and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995. The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2020,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
InvestorsInnate
Pharma
Tel.: +33 (0)4 30 30 30 30investors@innate-pharma.com |
MediaInnate PharmaTracy Rossin
(Global/US)Tel.: +1 240 801 0076Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France)Tel.: +33 (0)9 81
87 46 72innate-pharma@atcg-partners.com |
1 Gauthier et al., Cell 2019
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jul 2023 to Jul 2024